Form 8-K - Current report:
SEC Accession No. 0000899923-24-000054
Filing Date
2024-11-07
Accepted
2024-11-07 16:11:41
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-20241107.htm   iXBRL 8-K 38043
2 EX-99.1 Q3-2024 EARNINGS RELEASE mygn-ex991xearningsrelease.htm EX-99.1 454097
  Complete submission text file 0000899923-24-000054.txt   680107

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20241107.xsd EX-101.SCH 2021
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20241107_def.xml EX-101.DEF 14426
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20241107_lab.xml EX-101.LAB 25279
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20241107_pre.xml EX-101.PRE 15012
17 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20241107_htm.xml XML 2804
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 241435791
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)